Shattuck Labs, Inc. (NASDAQ:STTK) Short Interest Update

Shattuck Labs, Inc. (NASDAQ:STTK) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 2,198,677 shares, a growth of 113.8% from the December 31st total of 1,028,366 shares. Currently, 3.9% of the shares of the company are sold short. Based on an average daily trading volume, of 791,757 shares, the days-to-cover ratio is currently 2.8 days. Based on an average daily trading volume, of 791,757 shares, the days-to-cover ratio is currently 2.8 days. Currently, 3.9% of the shares of the company are sold short.

Hedge Funds Weigh In On Shattuck Labs

A number of institutional investors have recently made changes to their positions in the stock. Turtle Creek Wealth Advisors LLC bought a new stake in shares of Shattuck Labs during the 3rd quarter worth $29,000. Virtu Financial LLC bought a new position in Shattuck Labs in the third quarter valued at $38,000. Squarepoint Ops LLC purchased a new position in shares of Shattuck Labs during the 3rd quarter valued at about $46,000. Mallini Complete Financial Planning LLC purchased a new stake in Shattuck Labs in the fourth quarter worth approximately $83,000. Finally, AQR Capital Management LLC grew its position in Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after acquiring an additional 31,355 shares during the last quarter. Institutional investors own 58.74% of the company’s stock.

Analyst Upgrades and Downgrades

STTK has been the topic of a number of research analyst reports. HC Wainwright upgraded shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 target price on the stock in a research note on Monday, December 1st. Piper Sandler started coverage on Shattuck Labs in a research note on Wednesday. They issued an “overweight” rating and a $15.00 price objective on the stock. Citigroup raised their target price on Shattuck Labs from $2.00 to $4.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Shattuck Labs in a research note on Thursday, January 22nd. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $6.20.

Shattuck Labs Trading Down 2.9%

Shares of STTK stock traded down $0.12 during trading hours on Friday, reaching $3.95. The stock had a trading volume of 55,682 shares, compared to its average volume of 872,154. The stock’s fifty day simple moving average is $3.49 and its 200 day simple moving average is $2.23. The firm has a market capitalization of $249.96 million, a PE ratio of -3.88 and a beta of 1.53. Shattuck Labs has a 12 month low of $0.69 and a 12 month high of $4.89.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. The firm had revenue of $1.00 million during the quarter. As a group, equities research analysts anticipate that Shattuck Labs will post -1.48 EPS for the current fiscal year.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical?stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten?carrier conjugate technology designed to generate high?affinity drug?specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood?brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.